TrialCancer science2018

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.

Hiroaki Akamatsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.